Similarly, unfavorable results were observed in a randomized study comparing gefitinib to methotrexate in recurrent and/or metastatic HNSCC, where the EGFR gene copy number did not predict a survival advantage in individuals treated with the EGFR-TKI. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.